Azacitidine as maintenance therapy in pediatric de novo acute myeloid leukemia
BackgroundRelapse remains a major challenge in pediatric acute myeloid leukemia (AML), particularly in patients ineligible for hematopoietic stem cell transplantation (HSCT). Hypomethylating agents like azacitidine are hypothesized to target residual disease, but their efficacy and safety as mainten...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2025-12-01
|
| Серія: | Frontiers in Immunology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1696125/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|